Leukemia and Lymphoma: A Cost of Ng Business for Adaptive Immunity

Genes and Development - United States
doi 10.1101/gad.1446506
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Cold Spring Harbor Laboratory

Related search

Without Adaptive Immunity, There’s a Cost to Responding STAT

Cell Metabolism
Cell BiologyMolecular BiologyPhysiology
2018English

The (Interactional) Business of Ng Business

English

Cost of Disease Progression in Patients With Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non‐Hodgkin's Lymphoma

Oncologist
Cancer ResearchMedicineOncology
2019English

Defective Epidermal Innate Immunity and Resultant Superficial Dermatophytosis in Adult T-Cell Leukemia/Lymphoma

Clinical Cancer Research
Cancer ResearchOncology
2012English

Discovery of a BTK/MNK Dual Inhibitor for Lymphoma and Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2015English

Boosting Adaptive Immunity: A New Role for PAFR Antagonists

Scientific Reports
Multidisciplinary
2016English

Nanoparticles—Emerging Potential for Managing Leukemia and Lymphoma

Frontiers in Bioengineering and Biotechnology
BioengineeringBiomedical EngineeringHistologyBiotechnology
2017English

Complement as a Regulator of Adaptive Immunity

Seminars in Immunopathology
AllergyImmunology
2017English

Lymphoma and Leukemia During Pregnancy

Women's Health
Medicine
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy